Literature DB >> 18774662

Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies.

Cristina Seki1, Blanca Robiolo, Osvaldo Periolo, Marcela Iglesias, Alejandra D'Antuono, Eduardo Maradei, Virginia Barros, José La Torre, Nora Mattion.   

Abstract

Monoclonal antibodies (MAbs) developed against different foot-and-mouth disease virus (FMDV) vaccine strains were extensively used to study any possible antigenic variations during vaccine production in Argentine facilities. Additionally, a typing ELISA using strain specific MAbs was developed to detect potential cross contaminations among FMDV strains in master and working seeds with high specificity and sensitivity and to confirm strains identity in formulated vaccines. This assay was carried out for the South American strains currently in use in production facilities in Argentina (A24/Cruzeiro, A/Argentina/01, O1/Campos and C3/Indaial) and for the strain O/Taiwan, produced only for export to Asia. These non-cross reactive MAbs were also used to analyze the integrity of viral particles belonging to each one of the individual strains, following isolation of 140S virions by means of sucrose density gradients from the aqueous phase of commercial polyvalent vaccines. Antigenic profiles were defined for FMDV reference strains using panels of MAbs, and a coefficient of correlation of reactivity with these panels was calculated to establish consistent identity upon serial passages of master and production seeds. A comparison of vaccine and field strain antigenic profiles performed using coefficients of correlation allowed the rapid identification of two main groups of serotype A viruses collected during the last FMD epidemic in Argentina, whose reactivity matched closely to A/Argentina/2000 and A/Argentina/2001 strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774662     DOI: 10.1016/j.vetmic.2008.07.011

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Early adaptive immune responses in the respiratory tract of foot-and-mouth disease virus-infected cattle.

Authors:  J Pega; D Bucafusco; S Di Giacomo; J M Schammas; D Malacari; A V Capozzo; J Arzt; C Pérez-Beascoechea; E Maradei; L L Rodríguez; M V Borca; M Pérez-Filgueira
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

2.  Comparison of strategies for the production of FMDV empty capsids using the baculovirus vector system.

Authors:  V Ruiz; A C Mignaqui; M C Nuñez; E Reytor; J M Escribano; A Wigdorovitz
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

3.  Novel Capsid-Specific Single-Domain Antibodies with Broad Foot-and-Mouth Disease Strain Recognition Reveal Differences in Antigenicity of Virions, Empty Capsids, and Virus-Like Particles.

Authors:  Haozhou Li; Aldo Dekker; Shiqi Sun; Alison Burman; Jeroen Kortekaas; Michiel M Harmsen
Journal:  Vaccines (Basel)       Date:  2021-06-08

4.  Transient gene expression in serum-free suspension-growing mammalian cells for the production of foot-and-mouth disease virus empty capsids.

Authors:  Ana Clara Mignaqui; Vanesa Ruiz; Sylvie Perret; Gilles St-Laurent; Parminder Singh Chahal; Julia Transfiguracion; Ayelén Sammarruco; Victoria Gnazzo; Yves Durocher; Andrés Wigdorovitz
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

5.  Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.

Authors:  Ming Yang; Wanhong Xu; Melissa Goolia; Zhidong Zhang
Journal:  Virol J       Date:  2014-08-01       Impact factor: 4.099

6.  Isolation of Single-Domain Antibody Fragments That Preferentially Detect Intact (146S) Particles of Foot-and-Mouth Disease Virus for Use in Vaccine Quality Control.

Authors:  Michiel M Harmsen; Julian Seago; Eva Perez; Bryan Charleston; Phaedra L Eblé; Aldo Dekker
Journal:  Front Immunol       Date:  2017-08-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.